Literature DB >> 9506326

Vasodilatory effects of B-type natriuretic peptide are impaired in patients with chronic heart failure.

M Nakamura1, N Arakawa, H Yoshida, S Makita, H Niinuma, K Hiramori.   

Abstract

BACKGROUND: B-type natriuretic peptide (BNP) and atrial natriuretic peptide (ANP) are secreted from the heart and are thought to be equally important factors in the regulation of vascular tone in health and in congestive heart failure (CHF). However, no studies directly compare vasodilator effects of these peptides in healthy subjects and in patients with CHF.
METHODS: Plethysmography was used to determine the vasodilatory effects of BNP and to compare these to the effects of ANP in patients with CHF (n = 15) and age-matched healthy subjects (n = 16). Graded doses of ANP and BNP (8, 16, 32, and 48 pmol/min per 100 ml of tissue volume for both) were administered randomly into the brachial artery. Forearm blood flow (FBF) was measured, and cyclic GMP (cGMP) spillover was calculated.
RESULTS: Responses in FBF to both peptides in CHF were significantly lower than those of healthy subjects (BNP p < 0.05; ANP p < 0.01). Similarly, forearm spillover of cGMP was significantly lower in CHF than in healthy subjects (BNP p < 0.05; ANP p < 0.01). When vascular responses in healthy subjects were compared between BNP and ANP, BNP-induced changes in FBF (p < 0.05) and forearm cGMP spillover (p < 0.01) were significantly less than changes induced by ANP. In CHF, though, FBF change and cGMP spillover induced by the two peptides were not significantly different.
CONCLUSIONS: These results suggest that the metabolism and action of these natriuretic peptides in CHF may differ from the healthy state.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9506326     DOI: 10.1016/s0002-8703(98)70316-3

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  11 in total

1.  Atrial natriuretic peptide promotes cardiomyocyte survival by cGMP-dependent nuclear accumulation of zyxin and Akt.

Authors:  Takahiro Kato; John Muraski; Yan Chen; Yasuyuki Tsujita; Jason Wall; Christopher C Glembotski; Erik Schaefer; Mary Beckerle; Mark A Sussman
Journal:  J Clin Invest       Date:  2005-10       Impact factor: 14.808

2.  Increasing aminoterminal-pro-B-type natriuretic peptide precedes the development of arterial hypertension: the multiethnic study of atherosclerosis.

Authors:  Otto A Sanchez; David R Jacobs; Hossein Bahrami; Carmen A Peralta; Lori B Daniels; João A Lima; Alan Maisel; Daniel A Duprez
Journal:  J Hypertens       Date:  2015-05       Impact factor: 4.844

3.  Slower onset of vasodilating action of brain natriuretic peptide (BNP) compared to atrial natriuretic peptide (ANP) in human forearm resistant vessels.

Authors:  Hironobu Minami; Takanori Yasu; Tatsuya Tagawa; Ken Yamakawa; Shinichiro Ueda
Journal:  Eur J Clin Pharmacol       Date:  2008-07-12       Impact factor: 2.953

4.  C-Type Natriuretic Peptide Improves Left Ventricular Functional Performance at Rest and Restores Normal Exercise Responses after Heart Failure.

Authors:  Tiankai Li; Heng-Jie Cheng; Nobuyuki Ohte; Hiroshi Hasegawa; Atsushi Morimoto; David M Herrington; William C Little; Weimin Li; Che Ping Cheng
Journal:  J Pharmacol Exp Ther       Date:  2016-03-29       Impact factor: 4.030

5.  The cyclic guanosine monophosphate/B-type natriuretic peptide ratio and mortality in advanced heart failure.

Authors:  Patrícia Lourenço; José Paulo Araújo; Ana Azevedo; António Ferreira; Paulo Bettencourt
Journal:  Eur J Heart Fail       Date:  2009-02       Impact factor: 15.534

6.  Prolonged effects of B-type natriuretic peptide infusion on cardiac remodeling after sustained myocardial injury.

Authors:  Isaac George; Brad Morrow; Kai Xu; Geng-Hua Yi; Jeffrey Holmes; Ed X Wu; Zhihe Li; Andrew A Protter; Mehmet C Oz; Jie Wang
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-06-12       Impact factor: 4.733

7.  The associations between metabolic variables and NT-proBNP are blunted at pathological ranges: the Multi-Ethnic Study of Atherosclerosis.

Authors:  Otto A Sanchez; Daniel A Duprez; Hossein Bahrami; Lori B Daniels; Aaron R Folsom; Joao A Lima; Alan Maisel; Carmen A Peralta; David R Jacobs
Journal:  Metabolism       Date:  2013-11-27       Impact factor: 8.694

8.  Natriuretic peptides and nitric oxide stimulate cGMP synthesis in different cellular compartments.

Authors:  Leslie A Piggott; Kathryn A Hassell; Zuzana Berkova; Andrew P Morris; Michael Silberbach; Thomas C Rich
Journal:  J Gen Physiol       Date:  2006-06-12       Impact factor: 4.086

9.  Dipeptidyl-peptidase 4 inhibition and the vascular effects of glucagon-like peptide-1 and brain natriuretic peptide in the human forearm.

Authors:  Jessica K Devin; Mias Pretorius; Hui Nian; Chang Yu; Frederic T Billings; Nancy J Brown
Journal:  J Am Heart Assoc       Date:  2014-08-26       Impact factor: 5.501

Review 10.  Chronic heart failure as a state of reduced effectiveness of the natriuretic peptide system: implications for therapy.

Authors:  Javier Díez
Journal:  Eur J Heart Fail       Date:  2016-10-21       Impact factor: 15.534

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.